Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All molnupiravir studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchMolnupiravirMolnupiravir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   All Outcomes    Recent:   
0 0.5 1 1.5 2+ Hospitalization 65% Improvement Relative Risk Clinical improvement 53% Improvement in Ct value 48% Molnupiravir  Sinha et al.  EARLY TREATMENT  RCT Is early treatment with molnupiravir beneficial for COVID-19? RCT 1,218 patients in India (May - August 2021) Lower hospitalization (p=0.0053) and greater improvement (p=0.013) c19early.org Sinha et al., Cureus, November 2022 Favors molnupiravir Favors control

Efficacy and Safety of Molnupiravir in Mild COVID-19 Patients in India

Nov 2022  
  Post
  Facebook
Share
  Source   PDF   All   Meta
RCT 1,218 outpatients in India, showing lower hospitalization, better clinical improvement, and improved viral clearance with molnupiravir.
Concerns have been raised that the mutagenic mechanism of action may create dangerous variants or cause cancer Chamod, Gruber, Hadj Hassine, Huntsman, Marikawa, Swanstrom, Waters, Zhou, Zibat. Multiple analyses have identified variants potentially created by molnupiravir Fountain-Jones, Kosakovsky Pond, Sanderson, twitter.com.
risk of hospitalization, 65.3% lower, RR 0.35, p = 0.005, treatment 9 of 608 (1.5%), control 26 of 610 (4.3%), NNT 36.
risk of no clinical improvement, 52.8% lower, RR 0.47, p = 0.01, treatment 16 of 608 (2.6%), control 34 of 610 (5.6%), NNT 34, day 14.
relative improvement in Ct value, 48.4% better, RR 0.52, p < 0.001, treatment mean 9.5 (±7.0) n=608, control mean 4.9 (±10.6) n=610, day 14.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Sinha et al., 14 Nov 2022, Randomized Controlled Trial, India, peer-reviewed, 17 authors, study period May 2021 - August 2021, average treatment delay 2.0 days, trial CTRI/2021/05/033739. Contact: leela.t@hetero.com.
This PaperMolnupiravirAll
Efficacy and Safety of Molnupiravir in Mild COVID-19 Patients in India
Shubhadeep Sinha, Vasanth Kumar Suram, Sreenivasa S Chary, Veer Sunil Naik, Veer Bahadur Singh, Manish K Jain, Chandra P Suthar, Swapnav Borthakur, Vinayak Sawardekar, Noushadali Sk, Naveen Reddy, Leela Talluri, Pankaj Thakur, Mohan Reddy, Muralidhar Panapakam, Ramya Vattipalli
Cureus, doi:10.7759/cureus.31508
Background At the peak of the coronavirus disease 2019 (COVID-19) pandemic, the need for an orally administered agent to prevent the progression of acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection became increasingly evident, which was the impetus behind our investigations with molnupiravir. Molnupiravir has been shown to be effective in preventing hospitalizations and/or clinical complications in patients with mild-to-moderate COVID-19. In this study, we evaluate the efficacy and safety of molnupiravir in Indian patients with mild SARS-CoV-2 infection and at least one risk factor for disease progression (CTRI/2021/05/033739). Methodology This was a phase III, multicenter, randomized, open-label, controlled study conducted in Indian adults aged 18-60 years with mild SARS-CoV-2, reverse transcription polymerase chain reaction (RT-PCR)-positive within 48 hours of enrollment in the study, and within five days of first symptom onset. Enrolled patients were randomized to treatment arms in a 1:1 ratio to receive molnupiravir or placebo in addition to the standard of care (SoC) for SARS-CoV-2 infection. The SoC was in compliance with Government of India guidelines that were in force at the time. The primary endpoint was the rate of hospitalization up to day 14. Safety endpoints included incidence of adverse events (AEs). Results Eligible patients were randomized in a 1:1 ratio to receive molnupiravir in addition to SoC treatment (n = 608) or SoC alone (n = 610). In the molnupiravir group, nine (1.48%) patients required hospitalization versus 26 (4.26%) patients in the control group (risk difference = -2.78%; 95% CI = -4.65, -0.90; p = 0.0053). Overall, 45 (3.70%) patients reported 47 AEs during the study, most of which were mild and resolved completely. The molnupiravir group reported 30 AEs compared to 17 AEs in the control group. Headache and nausea were the two most commonly reported AEs. Conclusions The molnupiravir arm showed a lower rate of hospitalization and a shorter time for the improvement of clinical symptoms coupled with early RT-PCR negativity. Molnupiravir was well tolerated, and AEs were mild and rare. The addition of molnupiravir to standard therapy has the potential to prevent the progression of mild COVID-19 disease to the severe form.
Additional Information
References
Cox, Wolf, Plemper, Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets, Nat Microbiol, doi:10.1038/s41564-020-00835-2
Fischer Wa 2nd, Eron, Jr, Holman, A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus, Sci Transl Med, doi:10.1126/scitranslmed.abl7430
Fischer, Eron, Holman, Molnupiravir, an oral antiviral treatment for COVID-19, medRxiv, doi:10.1101/2021.06.17.21258639
Iec Maharaja, Hospital, Ethics committee; Virinchi Hospitals Institutional Ethics Committee; Institutional Ethics Committee GGMC issued
Painter, Holman, Bush, Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2, Antimicrob Agents Chemother, doi:10.1128/AAC.02428-20
Singh, Singh, Singh, Misra, An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19, Diabetes Metab Syndr, doi:10.1016/j.dsx.2022.102396
Vasudevan, Ahlqvist, Mcgeough, A concise route to MK-4482 (EIDD-2801) from cytidine, Chem Commun (Camb), doi:10.1039/d0cc05944g
{ 'DOI': '10.7759/cureus.31508', 'ISSN': ['2168-8184'], 'URL': 'http://dx.doi.org/10.7759/cureus.31508', 'author': [ {'affiliation': [], 'family': 'Sinha', 'given': 'Shubhadeep', 'sequence': 'first'}, {'affiliation': [], 'family': 'N', 'given': 'Kumarasamy', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Suram', 'given': 'Vasanth Kumar', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Chary', 'given': 'Sreenivasa S', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Naik', 'given': 'Sunil', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Singh', 'given': 'Veer Bahadur', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Jain', 'given': 'Manish K', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Suthar', 'given': 'Chandra P', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Borthakur', 'given': 'Swapnav', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Sawardekar', 'given': 'Vinayak', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Sk', 'given': 'Noushadali', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Reddy', 'given': 'Naveen', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Talluri', 'given': 'Leela', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Thakur', 'given': 'Pankaj', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Reddy', 'given': 'Mohan', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Panapakam', 'given': 'Muralidhar', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Vattipalli', 'given': 'Ramya', 'sequence': 'additional'}], 'container-title': 'Cureus', 'content-domain': {'crossmark-restriction': False, 'domain': []}, 'created': { 'date-parts': [[2022, 11, 15]], 'date-time': '2022-11-15T04:33:55Z', 'timestamp': 1668486835000}, 'deposited': { 'date-parts': [[2022, 11, 15]], 'date-time': '2022-11-15T04:34:01Z', 'timestamp': 1668486841000}, 'indexed': { 'date-parts': [[2022, 11, 16]], 'date-time': '2022-11-16T05:42:36Z', 'timestamp': 1668577356316}, 'is-referenced-by-count': 0, 'issued': {'date-parts': [[2022, 11, 14]]}, 'language': 'en', 'link': [ { 'URL': 'https://www.cureus.com/articles/118243-efficacy-and-safety-of-molnupiravir-in-mild-covid-19-patients-in-india', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '4492', 'original-title': [], 'prefix': '10.7759', 'published': {'date-parts': [[2022, 11, 14]]}, 'published-print': {'date-parts': [[2022, 11, 14]]}, 'publisher': 'Cureus, Inc.', 'reference': [ { 'DOI': '10.1002/cpu.30542', 'doi-asserted-by': 'crossref', 'key': 'ref1', 'unstructured': 'FDA approves first treatment for COVID-19. (2020). Accessed. September ' '22, 2022: ' 'https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19.'}, { 'key': 'ref2', 'unstructured': 'COVID-19 treatment. investigational drugs and other therapies. (2022). ' 'Accessed: September 22, 2022: ' 'https://emedicine.medscape.com/article/2500116-overview.'}, { 'key': 'ref3', 'unstructured': 'FDA halts use of COVID drugs ineffective against omicron. (2022). ' 'Accessed. September 22, 2022: ' 'https://www.webmd.com/lung/news/20220125/fda_halts_covid_drugs.'}, { 'key': 'ref4', 'unstructured': 'Coronavirus (COVID-19) update. FDA authorizes new monoclonal antibody ' 'for treatment of COVID-19 that retains activity against omicron variant. ' '(2022). Accessed: September 22, 2022: ' 'https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-new-monoclonal-antibod....'}, { 'DOI': '10.1039/d0cc05944g', 'article-title': 'A concise route to MK-4482 (EIDD-2801) from cytidine', 'author': 'Vasudevan N', 'doi-asserted-by': 'publisher', 'journal-title': 'Chem Commun (Camb)', 'key': 'ref5', 'unstructured': 'Vasudevan N, Ahlqvist GP, McGeough CP, et al.. A concise route to ' 'MK-4482 (EIDD-2801) from cytidine. Chem Commun (Camb). 2020, 56:13363-4. ' '10.1039/d0cc05944g', 'volume': '56', 'year': '2020'}, { 'DOI': '10.1128/AAC.02428-20', 'article-title': 'Human safety, tolerability, and pharmacokinetics of molnupiravir, a ' 'novel broad-spectrum oral antiviral agent with activity against ' 'SARS-CoV-2', 'author': 'Painter WP', 'doi-asserted-by': 'publisher', 'journal-title': 'Antimicrob Agents Chemother', 'key': 'ref6', 'unstructured': 'Painter WP, Holman W, Bush JA, et al.. Human safety, tolerability, and ' 'pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral ' 'agent with activity against SARS-CoV-2. Antimicrob Agents Chemother. ' '2021, 65:e02428-20. 10.1128/AAC.02428-20', 'volume': '65', 'year': '2021'}, { 'DOI': '10.1101/2021.06.17.21258639', 'article-title': 'Molnupiravir, an oral antiviral treatment for COVID-19', 'author': 'Fischer W', 'doi-asserted-by': 'publisher', 'journal-title': 'medRxiv', 'key': 'ref7', 'unstructured': 'Fischer W, Eron JJ, Holman W, et al.. Molnupiravir, an oral antiviral ' 'treatment for COVID-19. medRxiv. 2021, 10.1101/2021.06.17.21258639', 'year': '2021'}, { 'key': 'ref8', 'unstructured': 'Merck and Ridgeback’s molnupiravir, an investigational oral antiviral ' 'COVID-19 treatment, receives special approval for emergency in Japan. ' '(2021). Accessed. September 22, 2022: ' 'https://www.businesswire.com/news/home/20211224005081/en/.'}, { 'key': 'ref9', 'unstructured': 'Emergency use authorization (EUA) for the emergency use of molnupiravir ' 'for the treatment of mild-to-moderate coronavirus disease 2019 ' '(COVID-19). (2022). Accessed. September 22, 2022: ' 'https://www.fda.gov/media/155053/download.'}, { 'DOI': '10.1016/j.dsx.2022.102396', 'article-title': 'An updated practical guideline on use of molnupiravir and comparison ' 'with agents having emergency use authorization for treatment of ' 'COVID-19', 'author': 'Singh AK', 'doi-asserted-by': 'publisher', 'journal-title': 'Diabetes Metab Syndr', 'key': 'ref10', 'unstructured': 'Singh AK, Singh A, Singh R, Misra A. An updated practical guideline on ' 'use of molnupiravir and comparison with agents having emergency use ' 'authorization for treatment of COVID-19. Diabetes Metab Syndr. 2022, ' '16:102396. 10.1016/j.dsx.2022.102396', 'volume': '16', 'year': '2022'}, { 'key': 'ref11', 'unstructured': 'Clinical guidance for management of adult COVID-19 patients, dated 22 ' 'Apr 2021. AIIMS/ICMR-COVID-19 National Task Force/Joint Monitoring Group ' '(Dte. GHS). Ministry of Health and Family Welfare, Government of India. ' '(2021). Accessed. September 22, 2022: ' 'https://dghs.gov.in/WriteReadData/Orders/202104231216553337715COVIDManagementAlgorithm_22Apr21.pdf.'}, { 'DOI': '10.1016/S1473-3099(20)30483-7', 'article-title': 'A minimal common outcome measure set for COVID-19 clinical research', 'doi-asserted-by': 'publisher', 'journal-title': 'Lancet Infect Dis', 'key': 'ref12', 'unstructured': 'A minimal common outcome measure set for COVID-19 clinical research. ' 'Lancet Infect Dis. 2020, 20.e192-7. 10.1016/S1473-3099(20)30483-7', 'volume': '20', 'year': '2020'}, { 'key': 'ref13', 'unstructured': 'World Health Organization - Uppsala Monitoring Centre System for ' 'standardised case causality assessment. (2018). Accessed. November 04, ' '2022: ' 'https://who-umc.org/media/164200/who-umc-causality-assessment_new-logo.pdf.'}, { 'DOI': '10.1038/s41564-020-00835-2', 'article-title': 'Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 ' 'blocks SARS-CoV-2 transmission in ferrets', 'author': 'Cox RM', 'doi-asserted-by': 'publisher', 'journal-title': 'Nat Microbiol', 'key': 'ref14', 'unstructured': 'Cox RM, Wolf JD, Plemper RK. Therapeutically administered ribonucleoside ' 'analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. ' 'Nat Microbiol. 2021, 6:11-8. 10.1038/s41564-020-00835-2', 'volume': '6', 'year': '2021'}, { 'DOI': '10.1126/scitranslmed.abl7430', 'article-title': 'A phase 2a clinical trial of molnupiravir in patients with COVID-19 ' 'shows accelerated SARS-CoV-2 RNA clearance and elimination of ' 'infectious virus', 'author': 'Fischer WA 2nd', 'doi-asserted-by': 'publisher', 'journal-title': 'Sci Transl Med', 'key': 'ref15', 'unstructured': 'Fischer WA 2nd, Eron JJ Jr, Holman W, et al.. A phase 2a clinical trial ' 'of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 ' 'RNA clearance and elimination of infectious virus. Sci Transl Med. 2022, ' '14:eabl7430. 10.1126/scitranslmed.abl7430', 'volume': '14', 'year': '2022'}, { 'key': 'ref16', 'unstructured': 'Merck and Ridgeback Biotherapeutics provide update on results from ' 'MOVe-OUT study of molnupiravir, an investigational oral antiviral ' 'medicine, in at risk adults with mild-to-moderate COVID-19. (2021). ' 'Accessed. September 22, 2022: ' 'https://www.merck.com/news/merck-and-ridgeback-biotherapeutics-provide-update-on-results-from-move-out-study-of-molnu....'}], 'reference-count': 16, 'references-count': 16, 'relation': {}, 'resource': { 'primary': { 'URL': 'https://www.cureus.com/articles/118243-efficacy-and-safety-of-molnupiravir-in-mild-covid-19-patients-in-india'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': ['Aerospace Engineering'], 'subtitle': [], 'title': 'Efficacy and Safety of Molnupiravir in Mild COVID-19 Patients in India', 'type': 'journal-article'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit